Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.32 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963575 | 0.87 | PDE7A (0.39) | FPR2AKR1B1PDE7AKMT2A | |
| SCHEMBL5964553 | 0.87 | PDE7A (0.45) | LMNAPDE7AKMT2A | |
| SCHEMBL5964262 | 0.87 | ALDH1A1 (0.44) | PDE7AKMT2A | |
| SCHEMBL5963550 | 0.87 | TSHR (0.42) | LMNAPDE7AKMT2A | |
| SCHEMBL5963581 | 0.84 | PDE7A (0.42) | AKR1B1PDE7AKMT2A | |
| SCHEMBL5964489 | 0.82 | FPR2 (0.40) | FPR2AKR1B1LMNAOPRM1OPRD1 | |
| SCHEMBL5964451 | 0.81 | PDE7A (0.38) | PDE7A | |
| SCHEMBL5963779 | 0.78 | PGR (0.43) | PDE7ATDP2 | |
| SCHEMBL5963586 | 0.76 | HAO1 (0.34) | FPR2LMNATDP2KMT2AAURKA | |
| SCHEMBL5964235 | 0.75 | SMN1; SMN2 (0.48) | PDE7AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | FPR2 2452/4885AKR1B1 4086/4885LMNA 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.